Zhaoke Ophthalmology (HKSE:06622) 5-Year Share Buyback Ratio : 0.00% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Zhaoke Ophthalmology's current 5-Year Share Buyback Ratio was 0.00%.

HKSE:06622's 5-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -12.5
* Ranked among companies with meaningful 5-Year Share Buyback Ratio only.

Competitive Comparison of Zhaoke Ophthalmology's 5-Year Share Buyback Ratio

For the Biotechnology subindustry, Zhaoke Ophthalmology's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhaoke Ophthalmology's 5-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's 5-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Zhaoke Ophthalmology 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Zhaoke Ophthalmology (HKSE:06622) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Zhaoke Ophthalmology 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » 5-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN

Website

https://www.zkoph.com

Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.

Executives

Mak Siu Hang Viola	2201 Interest of corporation controlled by you
Gic Private Limited	2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd	2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd	2101 Beneficial owner
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Fidelity China Special Situations Plc	2101 Beneficial owner
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Vms Holdings Limited	2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited	2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p.	2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p.	2201 Interest of corporation controlled by you

Zhaoke Ophthalmology Headlines

No Headlines